United States:
FDA Determines LUPRON DEPOT Not Withdrawn For Safety Or Effectiveness Reasons
27 October 2014
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
In the October 8, 2014, Federal Register, FDA published its
determination that LUPRON DEPOT (leuprolide acetate for depot
suspension), an injectable vial containing 3.75 milligrams of the
drug, was not withdrawn from sale for reasons of safety or
effectiveness.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Manatt Health: Health AI Policy Tracker
Manatt, Phelps & Phillips LLP
The purpose of this quarterly tracker is to identify key federal and state health AI policy activity. Below reflects federal legislative and regulatory activity to date related to AI...